Association between a promoter variant in the monoamine oxidase A gene and schizophrenia

Schizophrenia Research

Volumn 61, Issue 1, 2003, Pages 31-37

  Jönsson, Erik G ^a   Norton, Nadine ^b   Forslund, Kaj ^a   Mattila Evenden, Marja ^a   Rylander, Gunnar ^a   Åsberg, Marie ^a   Owen, Michael J ^b   Sedvall, Göran C ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Association; Genetics; Monoamine oxidase A (MAOA) gene; Schizophrenia

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SCHIZOPHRENIA;

EID: 0037400883     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00224-4     Document Type: Article

References (47)

1. Bach A.W., Lan N.C., Johnson D.L., Abell C.W., Bembenek M.E., Kwan S.W., Seeburg P.H., Shih J.C. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. U. S. A. 85:1988;4934-4938.
2. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am. J. Psychiatry. 135:1978;164-173.
3. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41:2001;237-260.
4. Cawthon R.M., Printar J.E., Haseltine F.P., Breakefield X.O. Differences in the structure of A and B forms of human monoamine oxidase. J. Neurochem. 37:1981;363-372.
5. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edn. 1988;Lawrence Erlbaum Associates, Hillsdale, NJ.
6. Coron B., Campion D., Thibaut F., Dollfus S., Preterre P., Langlois S., Vasse T., Moreau V., Martin C., Charbonnier F., Laurent C., Mallet J., Petit M., Frebourg T. Association study between schizophrenia and monoamine oxidase A and B DNA polymorphisms. Psychiatry Res. 62:1996;221-226.
7. Dann J., DeLisi L.E., Devoto M., Laval S., Nancarrow D.J., Shields G., Smith A., Loftus J., Peterson P., Vita A., Comazzi M., Invernizzi G., Levinson D.F., Wildenauer D., Mowry B.J., Collier D., Powell J., Crowe R.R., Andreasen N.C., Silverman J.M., Mohs R., Murray R.M., Walters M.K., Lennon D.P., Hayward N.K., Albus M., Lerer B., Maier W., Crow T.J. A linkage study of schizophrenia to markers within Xp11 near the MAOB gene. Psychiatry Res. 70:1997;131-143.
8. Deckert J., Catalano M., Syagailo Y.V., Bosi M., Okladnova O., Di Bella D., Nöthen M.M., Maffei P., Franke P., Fritze J., Maier W., Propping P., Beckmann H., Bellodi L., Lesch K.P. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum. Mol. Genet. 8:1999;621-624.
9. DeLisi L.E., Neckers L.M., Staub R.A., Zalcman S.J., Wyatt R.J. Lymphocyte monoamine oxidase activity and chronic schizophrenia. Psychiatry Res. 2:1980;179-186.
10. DeLisi L.E., Wise C.D., Bridge T.P., Rosenblatt J.E., Wagner R.L., Morihisa J., Karson C., Potkin S.G., Wyatt R.J. A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients. Psychiatry Res. 4:1981;95-107.
11. DeLisi L.E., Devoto M., Lofthouse R., Poulter M., Smith A., Shields G., Bass N., Chen G., Vita A., Morganti C., Ott J., Crow T.J. Search for linkage to schizophrenia on the X and Y chromosomes. Am. J. Med. Genet. 54:1994;113-121.
12. Denney R.M., Koch H., Craig I.W. Association between monoamine oxidase A activity in human male skin fibroblasts and genotype of the MAOA promoter-associated variable number tandem repeat. Hum. Genet. 105:1999;542-551.
13. Donnelly C.H., Murphy D.L. Substrate and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem. Pharmacol. 26:1977;853-858.
14. Erdfelder E., Faul F., Buchner A. GPower: a general power analysis program. Behav. Res. Methods Instrum. Comput. 28:1996;1-11.
15. Geijer T., Neiman J., Rydberg U., Gyllander A., Jönsson E., Sedvall G., Valverius P., Terenius L. Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics. Eur. Arch. Psychiatry Clin. Neurosci. 244:1994;26-32.
16. Gustavsson J.P., Nöthen M.M., Jönsson E.G., Neidt H., Forslund K., Rylander G., Mattila-Eveden M., Sedvall G.C., Propping P., Åsberg M. No association between serotonin transporter gene polymorphisms and personality traits. Am. J. Med. Genet. 88:1999;430-436.
17. Hovatta I., Varilo T., Suvisaari J., Terwilliger J.D., Ollikainen V., Arajärvi R., Juvonen H., Kokko-Sahin M.L., Väisänen L., Mannila H., Lönnqvist J., Peltonen L. A genomewide screen for schizophrenia genes in an isolated Finnish subpopulation, suggesting multiple susceptibility loci. Am. J. Hum. Genet. 65:1999;1114-1124.
18. Jönsson, E., 1997. Genetic aspects on schizophrenia and cerebrospinal fluid monoamine metabolites. Focus on association studies with candidate genes. Thesis, Karolinska Institutet, p. 76.
19. Jönsson E.G., Nöthen M.M., Grünhage F., Farde L., Nakashima Y., Propping P., Sedvall G.C. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry. 4:1999;290-296.
20. Jönsson E.G., Nöthen M.M., Neidt H., Forslund K., Rylander G., Mattila-Evenden M., Åsberg M., Propping P., Sedvall G.C. Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. Schizophr. Res. 40:1999;31-36.
21. Jönsson E.G., Norton N., Gustavsson J.P., Oreland L., Owen M.J., Sedvall G.C. A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J. Psychiatr. Res. 34:2000;239-244.
22. Kendler K.S., Diehl S.R. The genetics of schizophrenia: a current, genetic-epidemiologic perspective. Schizophr. Bull. 19:1993;261-285.
23. Lan N.C., Heinzmann C., Gal A., Klisak I., Orth U., Lai E., Grimsby J., Sparkes R.S., Mohandas T., Shih J.C. Human monoamine oxidase A and B genes map to Xp11.23 and are deleted in a patient with Norrie disease. Genomics. 4:1989;552-559.
24. Laval S.H., Dann J.C., Butler R.J., Loftus J., Rue J., Leask S., Bass N., Comazzi M., Vita A., Nanko S., Shaw S., Peterson P., Shields G., Smith A.B., Stewart J., DeLisi L.E., Crow T.J. Evidence for linkage to psychosis and cerebral asymmetry (relative hand skill) on the X chromosome. Am. J. Med. Genet. 81:1998;420-427.
25. Levy E.R., Powell J.F., Buckle V.J., Hsu Y.P., Breakefield X.O., Craig I.W. Localization of human monoamine oxidase A gene to Xp11.23-11.4 by in situ hybridization: implications for Norrie disease. Genomics. 5:1989;368-370.
26. Meltzer H.Y., Duncavage M.B., Jackman H., Arora R., Tricou B., Young M. Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients. Am. J. Psychiatry. 139:1982;1242-1248.
27. Murphy D.L., Wyatt R.J. Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature. 238:1972;225-226.
28. Norton, N., Kirov, G., Zammit, S., Jones, G., Jones, S., Owen, R., Krawczak, M., Williams, N.M., O'Donovan, M.C., Owen, M.J., in press. Schizophrenia and functional polymorphisms in the MAOA and COMT genes: no evidence for association or epistasis. Am. J. Med. Genet.
29. Owen F., Bourne R.C., Crow T.J., Fadhli A.A., Johnstone E.C. Platelet monoamine oxidase activity in acute schizophrenia: relationship to symptomatology and neuroleptic medication. Br. J. Psychiatry. 139:1981;16-22.
30. Ozelius L., Hsu Y.P., Bruns G., Powell J.F., Chen S., Weyler W., Utterback M., Zucker D., Haines J., Trofatter J.A. Human monoamine oxidase gene (MAOA): chromosome position (Xp21-Xp11) and DNA polymorphism. Genomics. 3:1988;53-58.
31. Pintar J.E., Barbosa J., Francke U., Castligione C.M., Hawkins M. Jr., Breakefield X.O. Gene for monoamine oxidase type A assigned to the human X chromosome. J. Neurosci. 1:1981;166-175.
32. Sabol S.Z., Hu S., Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Genet. 103:1998;273-279.
33. Sham P.C., Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann. Hum. Genet. 59:1995;97-105.
34. Spitzer R.L., Williams J.B.W., Gibbon M. Structured clinical interview for DSM-III-R-non patient version (SCID-NP). 1986;Biometrics Research Department, New York State Psychiatric Institute, New York.
35. Stenström A., Hardy J., Oreland L. Intra- and extra-dopamine-synaptosomal localization of monoamine oxidase in striatal homogenates from four species. Biochem. Pharmacol. 36:1987;2931-2935.
36. Syagailo Y.V., Stöber G., Grässle M., Reimer E., Knapp M., Jungkunz G., Okladnova O., Meyer J., Lesch K.P. Association analysis of the functional monoamine oxidase A gene promoter polymorphism in psychiatric disorders. Am. J. Med. Genet. 105:2001;168-171.
37. van Rossum J.M. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. Brill H., Cole J.O., Deniker P., Hippius H., Bradley P.B. 5th Collegium Internationale Neuropsychopharmacologicum. 1967;321-329 Excerpta Medica, Amsterdam.
38. van Kammen D.P., Kelley M. Dopamine and norepinephrine activity in schizophrenia. An integrative perspective. Schizophr. Res. 4:1991;173-191.
39. Wei J., Hemmings G.P. Allelic association between dinucleotide repeats at the monoamine oxidase loci and schizophrenia. Eur. Psychiatr. 13:1998;407-410.
40. Wei J., Hemmings G.P. A study of linkage disequilibrium between polymorphic loci for monamine oxidases A and B in schizophrenia. Psychiatr. Genet. 9:1999;177-181.
41. Williams J., McGuffin P., Nöthen M.M., Owen M.J. Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. Lancet. 349:1997;1221.
42. Williams J., Spurlock G., Holmans P., Mant R., Murphy K., Jones L., Cardno A., Asherson P., Blackwood D., Muir W., Meszaros K., Aschauer H., Mallet J., Laurent C., Pekkarinen P., Seppala J., Stefanis C.N., Papadimitriou G.N., Macciardi F., Verga M., Pato C., Azevedo H., Crocq M.A., Gurling H., Kalsi G., Curtis D., McGuffin P., Owen M.J. A meta-analysis and transmission disequilbirium study of association between the dopamine D3 receptor gene and schizophrenia. Mol. Psychiatry. 3:1998;141-149.
43. Williams N.M., Rees M.I., Holmans P., Norton N., Cardno A.G., Jones L.A., Murphy K.C., Sanders R.D., McCarthy G., Gray M.Y., Fenton I., McGuffin P., Owen M.J. A two-stage genome scan for schizophrenia susceptibility genes in 196 affected sibling pairs. Hum. Mol. Genet. 8:1999;1729-1739.
44. Woolf B. On estimating the relation between blood group and disease. Ann. Hum. Genet. 19:1955;251-253.
45. Woolley D.W., Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. U. S. A. 40:1954;228-231.
46. Wyatt R.J., Murphy D.L., Belmaker R., Cohen S., Donnelly C.H., Pollin W. Reduced monoamine oxidase activity in platelets: a possible genetic marker for vulnerability to schizophrenia. Science. 179:1973;916-918.
47. Wyatt R.J., Potkin S.G., Murphy D.L. Platelet monoamine oxidase activity in schizophrenia: a review of the data. Am. J. Psychiatry. 136:1979;377-385.